|
1
|
Stordal B and Davey M: Understanding
cisplatin resistance using cellular models. IUBMB Life. 59:696–699.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Loehrer PJ and Einhorn LH: Drugs five
years later. Cisplatin Ann Intern Med. 100:704–713. 1984.
View Article : Google Scholar
|
|
3
|
Milosavljevic N, Duranton C, Djerbi N,
Puech PH, Gounon P, Lagadic-Gossmann D, Dimanche-Boitrel MT, Rauch
C, Tauc M, Counillon L, et al: Nongenomic effects of cisplatin:
Acute inhibition of mechanosensitive transporters and channels
without actin remodeling. Cancer Res. 70:7514–7522. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Windsor RE, Strauss SJ, Kallis C, Wood NE
and Whelan JS: Germline genetic polymorphisms may influence
chemotherapy response and disease outcome in osteosarcoma: A pilot
study. Cancer. 118:1856–1867. 2012. View Article : Google Scholar
|
|
5
|
Levi JA, Aroney RS and Dalley DN:
Haemolytic anaemia after cisplatin treatment. Br Med J (Clin Res
Ed). 282:2003–2004. 1981. View Article : Google Scholar
|
|
6
|
Hall MD, Okabe M, Shen DW, Liang XJ and
Gottesman MM: The role of cellular accumulation in determining
sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol
Toxicol. 48:495–535. 2008. View Article : Google Scholar
|
|
7
|
Champeris Tsaniras S, Kanellakis N,
Symeonidou IE, Nikolopoulou P, Lygerou Z and Taraviras S: Licensing
of DNA replication, cancer, pluripotency and differentiation: An
interlinked world? Semin Cell Dev Biol. 30:174–180. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Buolamwini JK: Cell cycle molecular
targets in novel anticancer drug discovery. Curr Pharm Des.
6:379–392. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Diaz-Moralli S, Tarrado-Castellarnau M,
Miranda A and Cascante M: Targeting cell cycle regulation in cancer
therapy. Pharmacol Ther. 138:255–271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brunelle JK and Letai A: Control of
mitochondrial apoptosis by the Bcl-2 family. J Cell Sci.
122:437–441. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gates MA, Vitonis AF, Tworoger SS, Rosner
B, Titus-Ernstoff L, Hankinson SE and Cramer DW: Flavonoid intake
and ovarian cancer risk in a population-based case-control study.
Int J Cancer. 124:1918–1925. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ong KC and Khoo HE: Biological effects of
myricetin. Gen Pharmacol. 29:121–126. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ross JA and Kasum CM: Dietary flavonoids:
Bioavailability, metabolic effects, and safety. Annu Rev Nutr.
22:19–34. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Basli A, Soulet S, Chaher N, Mérillon JM,
Chibane M, Monti JP and Richard T: Wine polyphenols: Potential
agents in neuro-protection. Oxid Med Cell Longev. 2012:8057622012.
View Article : Google Scholar
|
|
15
|
Zhang XH, Chen SY, Tang L, Shen YZ, Luo L,
Xu CW, Liu Q and Li D: Myricetin induces apoptosis in HepG2 cells
through Akt/p70S6K/bad signaling and mitochondrial apoptotic
pathway. Anticancer Agents Med Chem. 13:1575–1581. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Phillips PA, Sangwan V, Borja-Cacho D,
Dudeja V, Vickers SM and Saluja AK: Myricetin induces pancreatic
cancer cell death via the induction of apoptosis and inhibition of
the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer
Lett. 308:181–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zang W, Wang T, Wang Y, Li M, Xuan X, Ma
Y, Du Y, Liu K, Dong Z and Zhao G: Myricetin exerts
anti-proliferative, anti-invasive, and pro-apoptotic effects on
esophageal carcinoma EC9706 and KYSE30 cells via RSK2. Tumour Biol.
35:12583–12592. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim ME, Ha TK, Yoon JH and Lee JS:
Myricetin induces cell death of human colon cancer cells via
BAX/BCL2-dependent pathway. Anticancer Res. 34:701–706.
2014.PubMed/NCBI
|
|
19
|
Li B, Gao Y, Rankin GO, Rojanasakul Y,
Cutler SJ, Tu Y and Chen YC: Chaetoglobosin K induces apoptosis and
G2 cell cycle arrest through p53-dependent pathway in
cisplatin-resistant ovarian cancer cells. Cancer Lett. 356:418–433.
2015. View Article : Google Scholar
|
|
20
|
Darcy KM, Brady WE, McBroom JW, Bell JG,
Young RC, McGuire WP, Linnoila RI, Hendricks D, Bonome T and Farley
JH; Gynecologic Oncology Group. Associations between p53
overexpression and multiple measures of clinical outcome in
high-risk, early stage or suboptimally-resected, advanced stage
epithelial ovarian cancers A Gynecologic Oncology Group study.
Gynecol Oncol. 111:487–495. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang YI, Kim JH, Lee KT and Choi JH:
Costunolide induces apoptosis in platinum-resistant human ovarian
cancer cells by generating reactive oxygen species. Gynecol Oncol.
123:588–596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wilson TR, Johnston PG and Longley DB:
Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer
Drug Targets. 9:307–319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu T, Hannafon B, Gill L, Kelly W and
Benbrook D: Flex-Hets differentially induce apoptosis in cancer
over normal cells by directly targeting mitochondria. Mol Cancer
Ther. 6:1814–1822. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ozören N and El-Deiry WS: Cell surface
death receptor signaling in normal and cancer cells. Semin Cancer
Biol. 13:135–147. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maggioni D, Nicolini G, Rigolio R, Biffi
L, Pignataro L, Gaini R and Garavello W: Myricetin and naringenin
inhibit human squamous cell carcinoma proliferation and migration
in vitro. Nutr Cancer. 66:1257–1267. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shiomi K, Kuriyama I, Yoshida H and
Mizushina Y: Inhibitory effects of myricetin on mammalian DNA
polymerase, topoisomerase and human cancer cell proliferation. Food
Chem. 139:910–918. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kong D, Ma S, Liang B, Yi H, Zhao Y, Xin
R, Cui L, Jia L and Liu X and Liu X: The different regulatory
effects of p53 status on multidrug resistance are determined by
autophagy in ovarian cancer cells. Biomed Pharmacother. 66:271–278.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kuo YC, Kuo PL, Hsu YL, Cho CY and Lin CC:
Ellipticine induces apoptosis through p53-dependent pathway in
human hepatocellular carcinoma HepG2 cells. Life Sci. 78:2550–2557.
2006. View Article : Google Scholar
|
|
30
|
Basu A and Haldar S: The relationship
between BcI2, Bax and p53: Consequences for cell cycle progression
and cell death. Mol Hum Reprod. 4:1099–1109. 1998. View Article : Google Scholar
|
|
31
|
Mihara M, Erster S, Zaika A, Petrenko O,
Chittenden T, Pancoska P and Moll UM: p53 has a direct apoptogenic
role at the mitochondria. Mol Cell. 11:577–590. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guan YQ, Li Z, Yang A, Huang Z, Zheng Z,
Zhang L, Li L and Liu JM: Cell cycle arrest and apoptosis of
OVCAR-3 and MCF-7 cells induced by co-immobilized TNF-α plus IFN-γ
on polystyrene and the role of p53 activation. Biomaterials.
33:6162–6171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ho JS, Ma W, Mao DY and Benchimol S:
p53-Dependent transcriptional repression of c-myc is required for
G1 cell cycle arrest. Mol Cell Biol. 25:7423–7431. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hermeking H and Eick D: Mediation of
c-Myc-induced apoptosis by p53. Science. 265:2091–2093. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gartel AL and Radhakrishnan SK: Lost in
transcription: p21 repression, mechanisms, and consequences. Cancer
Res. 65:3980–3985. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang XH, Zou ZQ, Xu CW, Shen YZ and Li D:
Myricetin induces G2/M phase arrest in HepG2 cells by inhibiting
the activity of the cyclin B/Cdc2 complex. Mol Med Rep. 4:273–277.
2011.PubMed/NCBI
|
|
37
|
Piccolo MT and Crispi S: The dual role
played by p21 may influence the apoptotic or anti-apoptotic fate in
cancer. J Cancer Res Updates. 1:189–202. 2012.
|
